Aclidinium is an inhaled long-acting anticholinergic used as a maintenance bronchodilator in patients with chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors.
- Mechanism
- Curator reviewed
Aclidinium is a long-acting, competitive, and reversible anticholinergic drug that is specific for the acetylcholine muscarinic receptors. It binds to all 5 muscarinic receptor subtypes to a similar affinity. Aclidinium's effects on the airways are mediated through the M3 receptor at the smooth muscle to cause bronchodilation. Prevention of acetylcholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours.
- Primary indication
- Aclidinium bromide inhalation powder is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.Curator reviewed · 2 structured indications
- Formula / weight
- C26H30NO4S2 · 484.651 g/mol (avg)
- First approval
- Canada, 2022 · United States, 2012 · European Union, 2016
- Code names
- LAS-34273
- Brand names
Resolves to
ASMXXROZKSBQIH-VITNCHFBSA-NSMILESOC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1What you can answer from here — as of September 13, 2026
Which drugs share a target with Aclidinium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account